Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Folia Biologica
|
June 5, 2003
A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients
Z Varga, P de Mulder, W Kruit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1994
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group
G Catimel, J B Vermorken, M Clavel, et al.
Water Research
|
August 6, 2018
High-resolution mapping and modeling of anammox recovery from recurrent oxygen exposure
D Seuntjens, J M Carvajal-Arroyo, M Ruopp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2008
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)
C M L van Herpen, L D Locati, J Buter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 1996
Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam
D Cunningham, M Dicato, J Verweij, et al.
British Journal of Cancer
|
March 5, 2004
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
I Bleumer, A Knuth, E Oosterwijk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2004
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study
D Schrijvers, C Van Herpen, J Kerger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 7, 2005
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
C N Sternberg, P de Mulder, J H Schornagel, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Folia Biologica
|
June 5, 2003
A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients
Z Varga, P de Mulder, W Kruit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1994
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group
G Catimel, J B Vermorken, M Clavel, et al.
Water Research
|
August 6, 2018
High-resolution mapping and modeling of anammox recovery from recurrent oxygen exposure
D Seuntjens, J M Carvajal-Arroyo, M Ruopp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2008
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)
C M L van Herpen, L D Locati, J Buter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 1996
Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam
D Cunningham, M Dicato, J Verweij, et al.
British Journal of Cancer
|
March 5, 2004
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
I Bleumer, A Knuth, E Oosterwijk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2004
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study
D Schrijvers, C Van Herpen, J Kerger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 7, 2005
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
C N Sternberg, P de Mulder, J H Schornagel, et al.
Page
of 2